Trial · NCT07884526
AI-CARE: A Novel AI-Driven Mobile Insulin Calculator Integrating Image- Based Carbohydrate Estimation and CGM
NCT07884526, Not applicable, Not yet recruiting, Tan Tock Seng Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. AI-CARE: A Novel AI-Driven Mobile Insulin Calculator Integrating Image- Based Carbohydrate Estimation and CGM. Trials, record NCT07884526. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884526
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AI-CARE: A Novel AI-Driven Mobile Insulin Calculator Integrating Image- Based Carbohydrate Estimation and CGM
- NCT number
- NCT07884526
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 48 participants, estimated
- Lead sponsor
- Tan Tock Seng Hospital
- Conditions
- Diabetes Mellitus
- Interventions
- AI-CARE, Usual Care Group
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to achieve target sample size | From enrollment to the end of follow-up at 12 weeks | Recruitment feasibility will be evaluated by measuring the time (in weeks) required to achieve the target sample size. |
| Primary | Eligibility rate | From enrollment to the end of follow-up at 12 weeks | Recruitment feasibility will also be measured by calculating the eligibility rate, which is the proportion of eligible participants among those screened. |
| Primary | Recruitment rate | From enrollment to the end of follow-up at 12 weeks | Recruitment feasibility will also be measured by calculating the recruitment rate, which is the proportion of enrolled participants among those eligible. |
| Primary | Retention and attrition rates | From enrollment to the end of follow-up at 12 weeks | Retention and attrition rates will also be calculated, with attrition defined as the proportion of participants who withdraw or are lost to follow-up during the 12-week intervention period. |
| Primary | Intervention engagement | From enrollment to the end of follow-up at 12 weeks | Intervention engagement will be assessed through application usage metrics, including the frequency of daily insulin calculator activation and the proportion of meals supported by AI-CARE. Acceptability will be further inferred from app usage patterns. |
| Primary | Intervention usability | From enrollment to the end of follow-up at 12 weeks | Usability will be evaluated using the validated mHealth App Usability Questionnaire (MAUQ) for Standalone mHealth Apps Used by Patients, which will be administered at Week 12. In the MAUQ questionnaire, there are 18 statements, for which participants indicate their level of agreement on a 7-point scale (1 - strongly disagree, 2 - disagree, 3 - somewhat disagree, 4 - neither agree nor disagree, 5 - somewhat agree, 6 - agree, 7 - strongly agree). To determine the usability of an app, calculate the total and determine the average of the responses to all statements. The higher the overall average, the higher the usability of the app. There is also a section for participants' written comments. Acceptability will be further inferred from participant feedback. |
| Secondary | Changes in glycaemic control (HbA1c) | From enrollment to the end of follow-up at 12 weeks | Changes in glycaemic control will be assessed using HbA1c (%). |
| Secondary | Continuous glucose monitoring-derived metrics | From enrollment to the end of follow-up at 12 weeks | Continuous glucose monitoring-derived metrics include Time in Range (TIR), Time Above Range (TAR) and Time Below Range (TBR). TIR is the percentage of time that blood glucose stays within the normal range. TAR is the percentage of time that blood glucose rises above the target range. TBR is the percentage of time that blood glucose falls below the target range. |
| Secondary | Body Weight | From enrollment to the end of follow-up at 12 weeks | Body weight will be measured in kilograms and evaluated to explore broader metabolic effects of the intervention. |
| Secondary | Body Mass Index (BMI) | From enrollment to the end of follow-up at 12 weeks | Weight (in kilograms) and height (in meters) will be aggregated to report BMI in kg/m\^2) and evaluated to explore broader metabolic effects of the intervention. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884526
GET https://conductscience.org/api/trials/v1/NCT07884526/registered